Piotr Wysocki recently shared on LinkedIn:

“Dear Colleagues,

As a Guest Editor, I invite you to submit your manuscripts devoted to various aspects of metronomic chemotherapy in cancer treatment to the Special Issue of Cancers.

Despite profound progress in cancer treatment and the development of many novel molecularly targeted agents, chemotherapy remains the backbone and most often used form of systemic therapy for oncological malignancies.

With the advent of targeted chemotherapy, which is based on antibody-drug conjugates, there is a discussion regarding if and for how long classical chemotherapy will remain in the armamentarium of medical oncologists. Nevertheless, classical chemotherapy is still routinely used in both curative and palliative settings, but the way oncologists use this therapeutic tool has significantly evolved over the last decades.

One essential step toward improving the safety and efficacy of chemotherapy, especially when administered in a palliative, long-term setting, is to administer cytotoxic drugs in a metronomic fashion. Metronomic chemotherapy represents a unique chemotherapeutic treatment modality that utilizes single- or multi-agent regimens administered in short or ultra-short intervals.

This strategy, owing to its excellent safety profile and multidirectional antitumor activity (inhibiting tumor cell proliferation, suppressing tumor-induced angiogenesis, and reversing immunosuppression), represents a unique but broadly unappreciated systemic treatment strategy. Moreover, metronomic chemotherapy may represent a unique therapeutic partner for many targeted agents (kinase inhibitors, immune checkpoint inhibitors, endocrine agents), and this concept is being evaluated in many recently initiated clinical studies.

The focus of this Special Issue includes the following: (a) describe the mechanisms of the action of metronomic chemotherapy; (b) present the potential of metronomic chemotherapy in the treatment of various cancers; (c) discuss the role of metronomic chemotherapy as a partner for novel strategies, combining it with molecularly targeted agents and immunotherapies; (d) underscore the role of metronomic chemotherapy in low- and middle-income countries, where, in many cases, it may offer an alternative to the novel, financially unavailable cancer treatments.

This special issue is now open for submission.

Dr. Piotr Wysocki Guest Editor.”

Source: Piotr Wysocki/LinkedIn

Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.

His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.

Cancers publishes Special Issues to gather papers on specific topics, fostering a community of authors and readers to explore the latest research and innovate new ideas and research paths. These Special Issues are coordinated by Guest Editors, who are experts in their respective fields.

Read other posts by Piotr Wysocki published on OncoDaily.